Showing posts with label JAMA. Show all posts
Showing posts with label JAMA. Show all posts

Thursday, September 10, 2009

Will Your Son Get the Gardasil Vaccine?

Share
Now that the FDA’s vaccine advisory panel has given the nod to Gardasil for boys and men, the FDA is almost certain to approve the new market.

Although several panel members expressed concerns about the unknown duration of Gardasil’s protection against four strains of the HPV virus, only one member voted no. That was Vicky Debold, PhD, RN, who is the panel’s consumer representative.

"It would be a mistake to go forward and recommend that boys be encouraged to take this vaccine,” Dr. Debold said, “until we understand what's going on with the safety issues that [are] cropping up in girls.”

The value and safety of Gardasil have been increasingly questioned of late, notably this month in JAMA. The FDA has warned that the vaccine demonstrably raises the risk of syncope and blood clots, although it believes that the potential benefits far outweigh the risks. Drs. Sheila and David Rothman noted in JAMA that there was no data available about the vaccine’s effect on natural immunity, replacement diseases, or human behavior, such as ditching annual exams. They questioned the assumption that defeating HPV strains 16 and 18 will lead to a marked reduction in cases of cervical cancer. And they expressed concern that consumers were pushed to get the vaccine without being given the unbiased information necessary to properly weigh risks versus benefits.

Meanwhile, the vaccine has been associated with various serious side effects, including neurological and autoimmune conditions, in a small percentage of girls who’ve received one or more doses of the vaccine. No link, however, has been demonstrated at this point. (On the bright side for the parents of boys, autoimmune disease, which can be triggered in susceptible individuals by environmental factors, is less common in males than in females.)

“I would love my daughter and my son to get a vaccination that would prevent any kind of HPV, but it has to be at no cost, and I don't mean financial cost, I mean at no health risk cost," Dr. Jacques Moritz, the director of gynecology at St Luke's Roosevelt Hospital, told CBS news.

For boys, the vaccine has fewer potential direct benefits than for girls. The FDA was asked to consider only its efficacy for preventing genital warts, which affect about one percent of the population. Although the human papillomavirus can cause anal, penile, perineal and oral cancers in men, such cancers are very rare and are not as directly traceable to HPV—only about 40 percent of penile cancers, for instance, are related to HPV. Many boys and men will get the vaccine mostly as a way of protecting future partners. That gesture that can only be applauded by any woman.

As always, parents need to educate themselves about risks and benefits and honestly assess their individual lifestyles and family histories. One would expect the parent of a child with any family or personal history of autoimmune disease to be particularly cautious. On the other hand, an individual or the parent of a child with a lifestyle known to strongly increase incidence of persistent HPV infection—a poor diet including few fruits and vegetables, a smoking habit, many sexual partners, frequent sleep deprivation, lousy hygiene habits—might be more enthusiastic about the vaccine and less concerned about possible side effects. Males should also know that not being circumcised also substantially raises the risk of both transient and persistent HPV infections. Even a transient infection (some 95 percent of HPV infections are simply shrugged off, virtually always leaving behind natural immunity to that particular strain) can cause a persistent infection in a partner.

We are, hopefully, long past the days when we assume that what’s good for one person (or many) is good for every individual. In the case of Gardasil, none of the available choices are risk-free.

So what do you think? Will you as parents be getting Gardasil for your sons, and will men be getting it for themselves?

Tuesday, August 25, 2009

Gardasil — Exempt from Truth in Advertising Standards?

Share
People who ask questions about Gardasil are invariably told that they’re scientific ignoramuses, endangering their children with their crazy paranoia. Last week, however, JAMA, the Journal of the American Medical Association, issued stinging critiques of the over-selling of the HPV vaccine and the potential skewing of any risk/benefits analysis. It was rare criticism from the medical profession.

The truth is, we have more legal protection from an under-powered blender than we do from a vaccine.

Gardasil could well be the best thing since the invention of SmartPhones. But it could also alter our life for the worse, permanently, or it could simply be a waste of time and money. Merck and the FDA are making highly educated guesses, but you’d never know that from the hype. As consumers, isn’t it time we started demanding a little respect and honesty? Don’t we deserve sufficient information to come to a reasonable decision?

Under the Federal Trade Commission Act, advertising must be truthful and fair, and it must not deceive. Advertisers must have evidence to back up their claims. An ad is considered deceptive if it either contains a statement or omits information that might well mislead consumers who are acting reasonably under the circumstances. It also must not omit information that is important to a consumer’s decision to use or buy the product.

With Gardasil’s unprecedented marketing, said Drs. Sheila and David Rothman in JAMA, “by making the vaccine’s target disease cervical cancer, the sexual transmission of HPV was minimized, the threat of cervical cancer to adolescents was maximized, and the sub-populations most at risk practically ignored…the material [put out by Merck-funded PMAs] did not address the full complexity of the issues surrounding the vaccine and did not provide balanced recommendations on the risks and benefits.”

Science can be defined as ‘what we know so far.’ Or as Dr. Charlotte Haug put it in her JAMA editorial about Gardasil, “medical knowledge is typically incomplete and ambiguous.” Often, what we think we know turns out to be wrong, or just the tip of the iceberg. It would be totally irrational to reject all medical science on the basis that we might find out something to the contrary later, but it is equally irrational to try to make a decision about a new treatment without being in possession of all the known facts, particularly when huge financial benefits to the vendor weigh in.

“GARDASIL is the only cervical cancer vaccine that helps protect against 4 types of human papillomavirus (HPV): 2 types that cause 70% of cervical cancer cases, and 2 more types that cause 90% of genital warts cases,” says Merck. “Be one less,” say the ads. The implication: if you don’t get Gardasil, you do get cervical cancer.

Here’s my Truth in Advertising version.

Gardasil targets the two strains of the HPV virus that currently cause 70 percent of cases of cervical cancer and two strains that cause genital warts. Your chance of dying from cervical cancer is extremely small if you have regular check-ups. HPV may also cause (even more rarely) cases of oral cancer, anal cancer, and penile cancer. We do not yet know whether Gardasil will be effective against these cancers and will not know for several decades, but the hypothesis seems likely to some degree.

You can reduce your small chance of developing HPV-related cancers dramatically by eating healthy foods, by not smoking, by limiting your sexual partners, and by undergoing regular screenings. 95 percent of cases of HPV are currently shrugged off by the body. You should consider your lifestyle honestly when making a risk/benefit analysis.

Gardasil may offer some further protection. After 3.6 years, the results from two randomized, placebo-controlled trials following 17,622 women who were vaccinated with Gardasil after showing no previous exposure to 14 HPV types and had normal Pap smears to begin with were:

· 17 to 22 percent reduction in ASC-US: atypical squamous cells of undetermined significanceassociated with a high-risk type of HPV

· 17 percent reduction in LSIL: low-grade squamous intraepithelial lesion

· 36 percent reduction in ASC-H: atypical squamous cells/cannot exclude high-grade squamous intraepithelial lesion

· 45 percent reduction in HSIL: high-grade squamous intraepithelial lesion

Colposcopies were reduced by 20 percent, cervical biopsies by 22 percent and surgery and other invasive treatments by 42 percent.

Protection against genital warts appears to be extremely good.

We do not know whether replacement diseases will occur should non-vaccine strains of the virus (there are more than 100, and at least 15 are known to be oncogenic) fill the biological niche left by vaccine strains. We do not believe that this is likely but the vaccine Prevnar has shown that it can happen.

We do not know how Gardasil will affect natural immunity to the more than 100 strains of HPV.

We do not know how long immunity will last and whether single, or perhaps multiple, booster shots will be necessary. We do not know whether, should immunity to HPV-16 and HPV-18 wear off, older adults will be able to fight off the virus as well as younger adults.

Data from the passive VAERS system that is used to monitor vaccine adverse events, along with data from clinical trials, appears to indicate that Gardasil is well-tolerated by the vast majority of individuals. The FDA has determined a slightly greater risk of fainting and associated injury and of blood clots.

Anecdotal evidence and VAERS reports associate Gardasil with an increased risk of auto-immune disease and neurological problems, including rapid-onset ALS, arthritis, Graves Disease, paralysis, seizures, chronic headache, etc., predominantly in very active girls, but no causal link has been found at this time and incidence does not occur at a very significantly greater rate than in the general population. Incidence of auto-immune disease, which may be triggered in genetically pre-disposed individuals and more often in women by environmental factors, is generally rising. We do not know why. We do not know if a rapidly increasing lifetime burden of vaccine adjuvants plays some part, although high levels of aluminum have reportedly been found in spinal taps from some affected girls.

There was concern that initial studies of Gardasil showed a 44.6 percent increase in CIN 2/3 (the highest grade of pre-cancerous lesion) in a sub-group of individuals who had existing vaccine-type infections at time of vaccination. Further analysis showed that an unbalanced proportion of these subjects may have had enhanced risk factors such as a current smoking habit or a history of cervicovaginal infection or STD. Background evidence provided to the committee approving Gardasil concluded that, after balancing risk factors and sub-dividing sub-groups, vaccination could be said to reduce CIN2/3 by a modest 5.5 percent. Overall, a combined figure for subgroup studies showed an enhanced risk of disease of 11.7 percent in subjects who tested positive for vaccine-relevant HPV at the beginning of the study.

You may wish to get an HPV test and/or a pregnancy test prior to vaccination. You may wish discuss the advisability of vaccination with your doctor if you or your family has a history of autoimmune disorders.

You should not get Gardasil if you’re allergic to yeast or if you’re pregnant or planning to become pregnant soon.

You should report any and all potential adverse reactions to VAERS, being sure to include valid contact information, and not just all immediately post-vaccination allergic reactions, as the CDC’s handout implies.

Friday, August 21, 2009

JAMA Nails the Problem with Gardasil — and Our Healthcare System

Share
With all the debate about the state of American health care going on, it’s interesting that this month’s Journal of the American Medical Association (JAMA) has—perhaps unintentionally—presented the Gardasil vaccine against the HPV virus as a microcosm of what’s wrong with our current system. Over-prescribing, “skewed” information for doctors, “surrogate endpoint” approval that can lead to ineffective or harmful drugs, irrational risk/benefit scenarios that are influenced by financial interests, medication rather than intelligent living—sound familiar?

More health care for those who don’t need it.

American health care, for those who can afford it, is often as excessive as a Hardee’s Thickburger. The Congressional Budget Office estimates that 700 billion per year, or 5 percent of the US GDP, goes to tests and procedures that don’t improve health outcomes in the least.

Drs. Sheila and David Rothman note that in “creating a market out of thin air,” as PharmExec aptly put it when naming Gardasil 2007 Brand of the Year, Merck’s HPV vaccine was pushed to the entire population, rather than to those who really need it.

Cervical cancer kills around 4,000 people every year in the US. The death rate has dropped impressively since annual Pap smears were introduced in the 50s, and continues to drop by about four percent each year. Indeed, a large percentage of deaths from cervical cancer can be attributed to lack of access to, or inattention to, routine health care. Roughly 40 percent of women in the US are unwilling or unable to get regular Pap smears, and Kaiser Permanente found that more than half of its members with cervical cancer had not done so.

The Gardasil campaign, say the Rothmans, “bypassed public health officials who would have spear-headed a risk-sensitive vaccination campaign…this manufacturer understandably wanted as many adolescents as possible to be vaccinated. But the pursuit of this goal was neither cost-effective nor equitable. It meant rather than concentrating on populations in geographic areas with excess cervical cancer mortality, including African Americans in the south, Latinos along the Texas-Mexico border and whites in Appalachia, the marketing campaign posited that every girl was at equal risk.”

At least impoverished girls in the regions the Rothmans describe can sometimes get the shots at taxpayer expense. Women in the developing world, alas, are far more vulnerable to cervical cancer than the average American woman; it is the leading cause of cancer-related deaths among women there and kills some 215,475 women annually. Limited or non-existent access to routine health care means that an HPV vaccine would probably be well worth the small risk—but it’s currently unaffordable.

One of the more compelling arguments for the current private health care system in the US is that without being able to eye the highly lucrative American market, many lifesaving technologies and medications would never be developed and implemented around the world. It’s possible…maybe…that Merck has it in mind to pay for Gardasil development costs and huge profit margins by over-selling to the American market—at $360 plus administration costs per kid—and then offer the vaccine at a fractional cost to the market that actually needs it.

Oops. Maybe not. In India the series runs at about $173; far, far out of reach for the average woman in a country where 42 percent of the population lives below the international poverty level of $1.25/day. Absent a massively expensive and ill-afforded government program, only the rich, who already have access to preventive health care, are able to get it. And with a population of 1.2 billion, any government program will necessarily have limited coverage.

Then again, Americans have to ask ourselves about the morality of injecting substances into our children partly in order to defray the cost of overseas health care, if that’s what we’re looking at. There’s a big difference between subsidizing MRI technology with your money and subsidizing a vaccination with your child’s body.

Better living through chemistry.

We Americans (and increasingly other nations, too) have shown that we’re willing to be told that pills, potions, and now vaccinations are a convenient answer to epidemics like Type 2 diabetes, heart disease, ADD and now HPV. Way better, in fact, than taking responsibility for our own health and using medications only as a last resort. We’re apparently quite willing to transfer our dollars from the farmers’ market to the pharmaceutical market.

What the Rothmans didn’t say: A good deal of the potential physical trauma caused by persistent (not transient) HPV infection can be avoided by lifestyle changes, particularly if they’re made early. People who smoke, eat a lousy diet with a tiny or non-existent vegetable/fruit component, and/or have multiple sexual partners, are at a dramatically greater risk of getting a persistent HPV infection that might lead to abnormal cervical cells. A healthy immune system enables people to shrug off the vast majority of highly prevalent HPV infections. Your initially tiny risk of getting a persistent infection increases by as much as 15 percent with each sexual partner, by at least 50 percent with a bad diet, and by up to 2,600 percent with a smoking habit. But Merck is not inclined to tell you that, and neither are most doctors—or at least, not with the same force that they’ll put into the vaccination sales job.

Who cares about ultimate effectiveness? Just approve it already!

The FDA commonly accepts “surrogate endpoints” when approving drugs. Because it can take too long and cost too much to take drug trials to the ultimate outcome, and because doing so could deprive other patients from potentially life-saving treatments, the FDA often looks instead at interim markers. For instance, it might approve a drug because it lowers blood pressure rather than waiting to see how many people in the study die of a stroke instead of sheer old age.

That’s very reasonable—except that we are then often “surprised” by the ineffectiveness or negative side effects of drugs like Avandia, Vytorin, Zetia, Vioxx. Medications are effective for some 60 percent of treated patients at best.

The approval of Gardasil was an even bigger jump than usual. The assumption was that if we can defeat the two oncogenic strains of HPV that are responsible for 70 percent of cases of cervical cancer, then we can reduce the number of cases by 70 percent. That’s how it’s sold to parents, at least by implication.

“No data were available to establish the duration of efficacy, possible adverse effects on natural immunity, whether vaccinated women will forgo Papanicolaou tests, and whether after suppressing HPV-16 and HPV-18 ‘other strains may emerge as significant oncogenic serotypes,’” note the Rothmans.

The last trial data showed Gardasil to be 17-45 percent effective in preventing pre-cancerous cells, with the most dangerous types at the lower end of the range. It is too early to tell much about potential replacement diseases and longevity. When a healthy system shrugs off a particular HPV strain, it virtually always retains a life-long immunity to infection with that type; we’re many years from knowing that about Gardasil and from understanding the implications of an infection in later years. Plus, the many oncogenic HPV strains not covered by Gardasil may move into the post-vaccination void. We just don’t know yet.

The FDA has also been curiously incurious about the growing burden of vaccines on developing bodies. At 50, I’ve had few vaccines in my life, and those mostly later; today’s average child will have had 26 by the time he’s just two years old. And they just keep coming. Spurred by the blockbuster success of Gardasil, there’s wild speculation in the vaccine industry and several new vaccines are well along in development.

Although the FDA requires “concomitant use” studies to prove that a new vaccine doesn’t affect the safety or effectiveness of existing vaccines given at the same time, little or no attention is given to the total lifetime burden of adjuvants like aluminum injected directly into the circulatory and lymphatic system. Some girls who have been hit with post-Gardasil autoimmune issues have been given lumbar punctures, which have revealed “high” levels of aluminum.

It’s all about the marketing/money, baby.

An even bigger jump was Merck’s saturation of the airwaves and doctors’ offices with the message that, as consumers inevitably inferred, not getting Gardasil equals cervical cancer. And here’s where the Rothmans really got going.

Their article lashed the professional medical associations (PMAs) that took Merck’s money to promote Gardasil to other health professionals—notably the American Society for Colposcopy and Cervical Pathology, the Society of Gynecologic Oncologists, and the American College Health Association.

The campaign was a shocking piece of marketing, and “that these arguments were delivered by PMAs is cause for concern,” wrote the Rothmans. “(PMAs) are obligated to provide members with evidence-based data so they can present relevant risks and benefits to their patients. To this end, PMAs must become more transparent about their relationship with industry, disclosing both the precise funding and technical assistance they have received to develop the promotional products. Under no circumstances should PMAs administer product-specific speakers’ bureaus, nor should they accept funding that requires them to report activity to the donor” (as actually happened).

Well, color me surprised. Pharma’s aggressive marketing techniques and slanted information have long permeated the entire medical profession.

A UCSF study found that doctors frequently make decisions about which drugs to prescribe based on “skewed” reports that are essentially written by the drug companies and then published in medical journals, typically emphasizing the positive reports of the trials and selectively reporting data. Trials with favorable outcomes were about five times more likely than those with unfavorable outcomes to be published. There were often many discrepancies between the results the FDA received and the published data; and one-fourth of the results of trials testing the effectiveness of new drugs were not published at all within five years after FDA approval.

Then there was the revelation that Merck had published an entire medical fake journal to push its products as well as keeping a list of researchers and doctors to be ‘discredited’ or ‘neutralized.’

Next, a UM study that found that researchers often didn’t properly disclose potential conflicts of interest in cancer studies. Where a potential conflict existed, randomized trials were more likely to link patient survival to a particular treatment.

Frankly, it’s a wonder that anyone trusts the medical industry at all. And that’s a shame. Good doctors, good researchers, imaginative and disciplined scientists, and effective, life-saving medications and treatments abound, but they’re drowned out by the shrill clamor of—shills.

Risk/benefit assessment

We all resent doctors who think they’re God, but we let them take on that role when we are not given, or do not search out, sufficient information. We should be able to trust them, but sometimes we can’t. Sometimes they themselves get skewed info.

Here’s how Dr. Charlotte Haug sums up Gardasil in JAMA. “If the potential benefits are substantial, most individuals would be willing to accept the risks. But the net benefit of the HPV vaccine to a woman is uncertain. Even if persistently infected with HPV, a woman most likely will not develop cancer if she is regularly screened. So rationally, she should be willing to accept only a small risk of harmful effects from the vaccine.

“When weighing evidence about risks and benefits, it is also appropriate to ask who takes the risk, and who gets the benefit. Patients and the public logically expect that only medical and scientific evidence is put in the balance. If other matters weigh in, such as profit for a company or financial or professional gains for physicians or groups of physicians, the balance is easily skewed. The balance will also tilt if the adverse events are not calculated correctly.”

And they’re not. As Deborah Kotz reported in the US News and World Report yesterday, 68 percent of reports of adverse events were filed in the VAERS system by Merck itself, and 89 percent didn't include "sufficient identifying information to allow medical review of the individual cases." The VAERS passive reporting system is notoriously fallible.

Kotz goes on to say that the results of the autopsy of Jenny Tetlock, who died of a mystery progressive paralysis after getting her Gardasil shots, showed that Jenny died from a “neurological disease that was ‘mediated by immune responses,’ leading to extensive damage in her spinal cord.” Her tissue samples will now be compared with those of Whitney Baird, who died of similar problems, but whose illness was never noted in the VAERS data base until Jenny’s case hit the internet.

It gave me great joy to read Dr. Haug’s words about rationally looking at the risk/reward ratio of Gardasil. I’ve been trying to look at the vaccine rationally since 2006, but maybe now that Dr. Haug,the Rothmans and JAMA have weighed in, our pediatrician will stop saying I’m an idiot for doing so.

Now if we can only apply the lessons to our healthcare system.